Table 2.
Performance of biomarkers showing significant differences (all in pg/ml except IFNβ in U/ml and S100A8/A9 in ng/ml).
| Marker | IBD (n = 40) | UC (n = 30) | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Stable Remission Median (95%CI) | Unstable Remission Median (95%CI) | AUC (95%CI) | Pa | P adj.b | Stable Remission Median (95%CI) | Unstable Remission Median (95%CI) | AUC (95%CI) | Pa | P adj.b | |
| IL-1Ra | 280 (188–651) | 511 (257–955) | 0.604 (0.42–0.78) | 0.222 | n.s. | 278 (151–438) | 515 (423–955) | 0.72 (0.53–0.91) | 0.040 | n.s. |
| IL-1β | 1.83 (0.8–2.25) | 3.6 (1.03–8.63) | 0.706 (0.53–0.87) | 0.030 | n.s. | 1.79 (0.4–2.25) | 3.62 (1.03–8.63) | 0.742 (0.56–0.92) | 0.023 | n.s. |
| IL-2 | 1.07 (0.1–2.93) | 0.1 (0.1–4.47) | 0.601 (0.42–0.78) | 0.253 | n.s. | 0.92 (0.1–2.93) | 0.1 (0.1–6.23) | 0.515 (0.30–0.73) | 0.886 | n.s. |
| IL-8 | 18.16 (12.51–34.72) | 26.47 (18.65–68.36) | 0.643 (0.46–0.82) | 0.182 | n.s. | 13.80 12.06–24.72) | 28.06 (20.60–68.36) | 0.769 (0.59–0.94) | 0.011 | n.s. |
| IL-13 | 6.51 (4.38–10.16) | 13.12 (8.37–29.69) | 0.678 (0.50–0.85) | 0.050 | n.s. | 5.31 (1.25–15.08) | 16.64 (9.12–29.69) | 0.733 (0.55–0.92) | 0.029 | n.s. |
| IL-15 | 4.41 (3.26–6.43) | 7.46 (4.0–9.4) | 0.69 (0.53–0.86) | 0.038 | n.s. | 4.57 (3.26–7.75) | 8.17 (4.91–9.40) | 0.729 (0.54–0.91) | 0.033 | n.s. |
| IL-18 | 85.36 (67.81–142.2) | 136.5 (118.9–166.3) | 0.726 (0.56- 0.89) | 0.015 | n.s. | 119 (66.34–156) | 131 (119–156) | 0.644 (0.44–0.85) | 0.187 | n.s. |
| IL-21 | 884 (126–1451) | 1779 (682–6266) | 0.722 (0.55–0.89) | 0.030 | n.s. | 898 (10–1451) | 2182 (1326–6266) | 0.782 (0.61–0.95) | 0.007 | 0.038 |
| IL-25 | 1132 (329–1580) | 2422 (617–6174) | 0.738 (0.57–0.90) | 0.010 | n.s. | 1098 (28.28–1687) | 2847 (617–8210) | 0.778 (0.61–0.95) | 0.009 | n.s. |
| IFNβ | 868 (10–1260) | 1713 (10–4492) | 0.692 (0.52- 0.86) | 0.037 | n.s. | 137 (10–1260) | 2501 (10–4492) | 0.733 (0.54–0.92) | 0.026 | n.s. |
| CXCL9 | 28.98 (16.74–62.15) | 116.5 (30.87–116.5) | 0.746 (0.59- 0.89) | 0.007 | 0.031 | 27.36 (13.51–37.82) | 62.97 (35.6–116.5) | 0.804 (0.64–0.96) | 0.004 | 0.012 |
| CXCL10 | 211 (159–259) | 268 (238–597) | 0.692 (0.52- 0.86) | 0.041 | n.s. | 209 (129–252) | 322 (238–597) | 0.796 (0.63–0.96) | 0.005 | 0.024 |
| CXCL11 | 91 (25.4–109.8) | 141 (67.4–191.5) | 0.700 (0.53 0.87) | 0.069 | n.s. | 35.31 (22.49–98.95) | 151 (46.53–192) | 0.787 (0.61–0.96) | 0.007 | 0.008 |
| G-CSF | 16.45 (89.6–20.86) | 53.69 (14.28–193.7) | 0.670 (0.49- 0.85) | 0.054 | n.s. | 17.57 (9.6–20.86) | 61.4 (20.1–194) | 0.769 (0.58–0.95) | 0.011 | n.s. |
| Galectin-1 | 37,870 (29,212–44,078) | 46,047 (30,311–59,136) | 0.658 (0.48–0.83) | 0.095 | n.s. | 38,373 (35,492–46,523) | 46,422 (38,745–60,042) | 0.752 (0.57–0.93) | 0.011 | 0.002 |
| S100A8/A9 | 2040 (1000–3100) | 3070 (2600–4500) | 0.757 (0.60- 0.91) | 0.005 | 0.016 | 2160 (1450–3200) | 3920 (3270–6100) | 0.849 (0.69–0.99) | 0.001 | < 0.001 |
CI confidence interval, AUC area under curve; asignificance of ROC analyses; badjusted significance using Kruskal Wallis test with Bonferroni post-hoc correction for multiple comparisons.
Significant P-values indicated in bold.